Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
PRQR
PRQR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PRQR News
ProQR Announces Underwritten Direct Offering, Shares Drop 20%
Jun 26 2026
NASDAQ.COM
ProQR Therapeutics Prices $50M Direct Offering of 27.6M Shares
Jun 25 2026
seekingalpha
ProQR Therapeutics Reports Positive Phase 1 Data for AX-0810
Jun 25 2026
seekingalpha
ProQR Reports Positive Data from AX-0810 Phase 1 Study
Jun 25 2026
NASDAQ.COM
Positive Phase 1 Study Results for AX-0810 Indicate Significant NTCP Modulation
Jun 25 2026
Newsfilter
ProQR Therapeutics Completes $50 Million Financing
Jun 25 2026
Newsfilter
ProQR Reports Q1 Financial Results with Significant Revenue Decline
May 12 2026
seekingalpha
ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks
Apr 08 2026
seekingalpha
PROQR FORMS AI ADVISORY BOARD AND PARTNERS WITH GINKGO BIOWORKS
Apr 08 2026
moomoo
ProQR Reports FY 2025 Financial Highlights
Mar 12 2026
seekingalpha
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
Nov 24 2025
NASDAQ.COM
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Oct 23 2025
NASDAQ.COM
ProQR Secures CTA Approval for AX-0810 and Plans Virtual Investor and Analyst Event on November 3, 2025
Oct 20 2025
Newsfilter
Cantor Fitzgerald Reiterates Overweight on ProQR Therapeutics, Maintains $8 Price Target
Jun 27 2025
Benzinga
JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target
Jun 27 2025
Benzinga
ProQR Therapeutics Submits Clinical Trial Application for AX-0810, Initiating First-in-Human Study Targeting Cholestatic Liver Diseases
Jun 26 2025
NASDAQ.COM
Show More News
